Skip to main content
Fig. 5 | Health Economics Review

Fig. 5

From: Safety, efficacy, and cost-effectiveness evaluation of systemic treatments for refractory colorectal cancer: a systematic review and modeling study

Fig. 5

Network meta-analysis results based on the cox proportional hazards model for OS and PFS. BSC, Best Supportive Care; N, number of patients; HR, Hazards ratios; OS, Overall Survival; PFS, Progression-free survival; RCT, Randomized Controlled Trial; REDo, regorafenib dose optimization; TAS-102, trifluridine/tipiracil; TAS-BEV, TAS-102 with bevacizumab

Back to article page

Health Economics Review

ISSN: 2191-1991

Contact us